T +1 212 819 7974
Kristen O'Shaughnessy is a litigation associate in White & Case's New York office and a member of the Firm’s global Competition Group. Ms. O'Shaughnessy's practice focuses on complex antitrust litigation and counseling. She regularly represents clients in the pharmaceutical industry.
Ms. O'Shaughnessy is Secretary of the Women's Network at White & Case, involved in coordinating female mentoring, networking events, and community outreach.
Prior to joining White & Case, Ms. O'Shaughnessy worked in Thailand advising clients on international intellectual property issues, including counseling the Thai Department of Intellectual Property on compliance with the Madrid Protocol and assisting a major pharmaceutical company with its global patent litigation strategy.
Ms. O'Shaughnessy holds a degree in engineering from Northwestern University.
Member of trial team representing a global pharmaceutical company in a preliminary injunction hearing in the Southern District of New York in an antitrust action challenging a new-product launch.
Representation of a major pharmaceutical company in two complex nationwide class actions alleging Walker Process fraud and illegal reverse payment settlements in violation of the Sherman Act as well as state antitrust and consumer protection laws.
Submission of an amicus brief to the United States Supreme Court in Kirtsaeng v. John Wiley & Sons on behalf of major national art museums, pertaining to museums' rights under the Copyright Act to display lawfully owned works of art. The Supreme Court cited the amicus brief in support of its landmark decision that the "first sale" doctrine applies to foreign-manufactured goods. The National Law Journal featured the brief as its "brief of the week" on July 25, 2012.
Assistant editor of the ABA Monopolization and Dominance Handbook, addressing the antitrust rules and principles governing unilateral business conduct.
"Recent Antitrust Developments: March and April 2015", May 12, 2015: ABA Section of Antitrust Law, Health Care and Pharmaceuticals Committee